Unmet needs in modern vaccinology: adjuvants to improve the immune response.
about
Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigenVaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine developmentChoice and Design of Adjuvants for Parenteral and Mucosal VaccinesVaccine Adjuvants: from 1920 to 2015 and BeyondThe expanding role of immunopharmacology: IUPHAR Review 16Safety assessment of adjuvanted vaccines: Methodological considerationsEnhanced protective immunity of the chimeric vector-based vaccine rAdV-SFV-E2 against classical swine fever in pigs by a Salmonella bacterial ghost adjuvantRecent advances of vaccine adjuvants for infectious diseasesNear-infrared laser adjuvant for influenza vaccinePreclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesInfluenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.Laser vaccine adjuvants. History, progress, and potentialImmunobiology of influenza vaccinesTargeted delivery of vaccine to dendritic cells by chitosan nanoparticles conjugated with a targeting peptide ligand selected by phage display technique.mRNA vaccine delivery using lipid nanoparticles.Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity.Development of newborn and infant vaccinesConvergent synthetic methodology for the construction of self-adjuvanting lipopeptide vaccines using a novel carbohydrate scaffold.A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.Liposomes as vaccine delivery systems: a review of the recent advances.Development of a minimal saponin vaccine adjuvant based on QS-21MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens.Second international congress on immunopharmacology: delivery systems and current strategies for drug design.Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi.Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine.InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunityDifferential adjuvant activities of TLR7 and TLR9 agonists inversely correlate with nitric oxide and PGE2 productionNanoemulsion-based mucosal adjuvant induces apoptosis in human epithelial cells.Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresolMeta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probesDisparate adjuvant properties among three formulations of "alum"Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates.Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applicationsTLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor modelsCo-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice.
P2860
Q21134130-57D179F1-48C5-47F9-8BF5-90FFA9CA8CA4Q21284959-DA14EA3B-0135-4C99-9B22-5AD05663C92FQ26783488-35565134-A622-43F5-8E3B-424BF970AEB2Q26783879-6883A1DB-84EC-4D4F-9DD8-1C42F14E626BQ26801862-B1FCDE69-F4B4-46AF-8C43-7C537DADF559Q27013956-F2B4A2FC-8AED-44C0-AB58-823BBC79C850Q27469061-2603192B-852F-4C19-8FBD-DC29C2AA136DQ28083679-A0ECFE03-C12C-4188-810A-EB66FF112863Q28536886-35B05B3E-60FD-4971-BEC1-59585894A133Q30352121-0F5C9C69-CBFD-4EDC-ACF9-484B7B1FE2E6Q30353863-40F2E1C8-31F2-40EE-A995-F96C6955CACFQ30368736-B89281FA-CAAE-4F90-B21B-3D84734DC933Q30413501-D79A13CC-7A6C-40CE-90FB-38962A127655Q30426771-670A73FB-C44D-4BAE-A146-B84B75C5FC42Q30869313-84A0D955-4EE7-4365-A938-1A96131890D1Q33711685-1B70B1C0-CA26-49D0-A585-5376F0BDE521Q33760871-02AB1C62-E30A-415F-AD56-3F1FFBFEA0C2Q33855899-3B28F6B6-895B-4EB3-BA9B-EFFE9D771F09Q33912121-C5E3ED9A-A837-4163-87F8-E75BE12FB22FQ33941914-FB96EA6E-D10C-45C0-8767-52AB5EDBAF1EQ34083111-D9F5F90E-2DCB-4583-844F-182D34460897Q34222728-14961884-19FB-49E4-8CF6-6589D41D3566Q34418761-E5D0C769-A6F4-45F1-9F52-BB30BC09C6B0Q34433407-BE2471B0-B550-4680-A8B9-4EDFCEC116B5Q34506918-A073F3B2-E63C-4997-8BAF-49D0F5F90E92Q34607450-453F8ABC-514C-40F7-9C78-E6CDB2B2C618Q34607470-153E8B68-EEC7-4701-8F58-CC0B571B0908Q35035621-6DC3272E-AACB-4305-ADA2-279945088AAAQ35108944-D95F948B-33FE-40AB-8571-D289967BD66BQ35392417-EE8467AF-F6A5-415F-B929-A084F485E31FQ35434746-11F5F998-9EFB-46B3-9231-5BDF961F5BC7Q35439931-9B73ED7A-4DFF-4F20-A07A-428B317937AAQ35539051-22C5245A-7F5F-4CE2-85DE-3F2D5AB036CEQ36009558-C336679D-D5C8-423E-A22A-C7721010D7D2Q36216866-6E4C30AD-F26A-405D-AF4A-EA77D9881F0AQ36522053-B8E219DB-BC24-4137-996F-5B8947AC80DFQ36754331-CE5224AD-9C4E-43AE-B389-22DFAB797EC1Q37177598-38669432-3617-4978-99A2-BC90B802A1C3Q37222202-F8CB4000-AA4D-4A3B-9016-6891704D8098Q37539243-AFD86FBE-475A-4412-823A-0ADBD2BC7D43
P2860
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@ast
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@en
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@nl
type
label
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@ast
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@en
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@nl
prefLabel
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@ast
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@en
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@nl
P1433
P1476
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
@en
P304
P356
10.1016/J.VACCINE.2010.07.021
P407
P478
28 Suppl 3
P577
2010-08-01T00:00:00Z